Current status of immunoprophylaxis with anti-D immunoglobin.
Engelfriet
C P
CP
Reesink
H W
HW
Judd
W J
WJ
Ulander
V-M
VM
Kuosmanen
M
M
Koskinen
S
S
Rouger
P
P
Morelati
F
F
Tantalo
V
V
Fujii
T
T
de Haas
M
M
van der Schoot
C E
CE
Overbeeke
M
M
Koelewijn
J
J
Bonsel
G
G
Vrijkotte
T
T
Zupańska
B
B
Martin-Vega
C
C
Parra Lopez
R
R
de Silva
M
M
Contreras
M
M
Panzer
S
S
Ulm
B
B
Mayr
W R
WR
D004363:Drug Utilization / Q000706:statistics & numerical data; D004899:Erythroblastosis, Fetal / Q000517:prevention & control*; D005060:Europe; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D011247:Pregnancy; D011248:Pregnancy Complications / Q000276:immunology / Q000628:therapy*; D011295:Prenatal Care / Q000706:statistics & numerical data*; D012203:Rh Isoimmunization / Q000628:therapy*; D018029:Rho(D) Immune Globulin / Q000627:therapeutic use*; D014481:United States
D018029:Rho(D) Immune Globulin